Delving into the Latest Updates on Jilin Tianheng Yingrui Pharmaceutical Co., Ltd. with Synapse

Overview

主要目的：考察空腹及餐后条件下，初步评价吉林天衡英睿制药有限公司研制的吲达帕胺缓释片（规格：1.5mg）与施维雅(天津)制药有限公司持证的吲达帕胺缓释片（商品名：纳催离，规格：1.5mg）在中国健康受试者中的人体生物等效性，为正式试验的方案设计提供依据。次要目的：评价吲达帕胺缓释片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main purpose: To investigate the human bioequivalence of indapamide sustained-release tablets (specification: 1.5 mg) developed by Jilin Tianheng Yingrui Pharmaceutical Co., Ltd. and indapamide sustained-release tablets (trade name: Nacuili, specification: 1.5 mg) certified by Servier (Tianjin) Pharmaceutical Co., Ltd. in healthy Chinese subjects under fasting and postprandial conditions, and to provide a basis for the design of the formal trial. Secondary purpose: To evaluate the safety of the test and reference preparations of indapamide sustained-release tablets in healthy subjects.

Start Date28 Feb 2025

Sponsor / Collaborator

Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

100 Clinical Results associated with Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

Login to view more data